Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Knight Therapeutics Inc. (T:GUD)

Business Focus: Proprietary & Advanced Pharmaceuticals

INK Edge Outlook

Mostly sunny as of November 01, 2021
For the latest outlook, get the company report

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for GUD within the last 6 months
See all filings within the past 6 months

Company News

Nov 11, 2021 07:30 ET
Knight Therapeutics Reports Third Quarter 2021
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2021. All currency amounts are in thousands...
Read full article
Nov 04, 2021 07:30 ET
Notice of Knight Therapeutics' Third Quarter 2021 Results Conference Call
Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2021 financial results on Thursday, November 11, 2021 prior to market opening. Following the release,...
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Nov 15, 20213,000,979182,034
Oct 31, 20212,818,94597,772
Oct 15, 20212,721,173194,447
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The Company's products include BIJUVA Estradiol and Progesterone capsule, IMVEXXY Estradiol vaginal inserts, IBSRELA Tenapanor tablets, TRELSTAR Prostate Triptorelin, TRELSTAR Endometriosis Triptorelin, ILUVIEN Fluocinolone acetonide, Nerlynx Neratinib Tablets, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex Bumetanide, Probuphine Buprenorphine implant, Movantik Naloxegol and Neuragen. It owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Its subsidiaries operates under United Medical, Biotoscana Farma and Laboratorio LKM.

See business summary



Search (past week) for $GUD.CA

  • No tweets found